Safety and Efficacy of Chimeric Antigen Receptor T Lymphocytes for Patients With Intermediate and Advanced Tumors
This was a single arm, open-label, single center, cohort study to determine the efficacy and safety of AMT-116 CAR-T cells in patients with moderate or far advanced non-small cell lung carcinoma (NSCLC) and squamous cell cancer of the head and neck (HNSCC)，AMT-253 CAR-T cells in patients with moderate or far advanced melanoma.
Melanoma|Non-small Cell Lung Cancer|Head and Neck Squamous Cell Carcinoma
BIOLOGICAL: AMT-116 CAR-T cells|BIOLOGICAL: AMT-253 CAR-T cells
Incidence of adverse events, 24 weeks|Overall Response Rate (ORR), 24 weeks|One year recurrence rate, 24 weeks
Progression-Free Survival(PFS), 24 weeks|Relapse Free Survival(RFS), 24 weeks
This was a single arm, open-label, single center, cohort study to determine the efficacy and safety of AMT-116 CAR-T cells in patients with moderate or far advanced non-small cell lung carcinoma (NSCLC) and squamous cell cancer of the head and neck (HNSCC)，AMT-253 CAR-T cells in patients with moderate or far advanced melanoma.